Navigation Links
Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
Date:11/27/2007

Top Scientists Meet for Global Conference On Stem Cell Therapy for Cardiovascular Diseases

Scientific Meeting on Ground-breaking Advances, Pioneering Innovations In Cell-Based Therapeutic Approaches to Cardiovascular Diseases

WHAT: The Cardiovascular Research Foundation (CRF) brings experts to New York City from around the world for the Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases. Dedicated to new advances in this emerging field, the three-day session will feature an in-depth review of cell-based therapies for myocardial repair and regeneration, angiogenesis and cutting-edge research findings. Highlights include:

  • Clinical Focus: Full-day programs for the discussion of heart attacks (ST elevation myocardial infarction, or STEMI) and congestive heart failure (CHF). Each will cover strategies using cell-based therapies to address the chronic ventricular dysfunction underlying these conditions.

  • Special Sessions on:
    • Cardiac Tissue Engineering, including exciting work in constructing blood vessels and cell sheets of myocardial tissue
    • Angiogenesis, including the use of stem cells derived from bone marrow, adipose, and other sources to synthesize functioning myocardium in patients with heart and peripheral vascular disease

  • Late Breaking Clinical Trials:

    • Results from two major trials (TOPCARE, REPAIR-AMI) of bone-marrow- or blood-derived progenitor cells for acute myocardial infarction will be reviewed by Dr. Andreas M. Zeiher
    • Intravenous allogeneic mesenchymal stem cells for acute myocardial infarction will be presented by Dr. Joshua M. Hare
    • MAGIC 5: combined approach using granulocyte colony stimulating factor (G-CSF), erythropoietin mobilization, and intracoronary cell infusion in patients with heart attack, presented in detail here by Dr. Hyo-Soo Kim
    • Bone marrow-derived stem cells for patients with chronic limb ischemia, presented by Dr. Brian Annex
    • Transplantation of bone marrow stem cells for persistent, refractory angina, presented and discussed by Drs. Douglas Losordo and Jorge Tuma
    • CausMic: A randomized, controlled study of myoblasts in patients with heart failure, first reported at AHA 2007, presented in detail here by Dr. Nabil Dib
    • Stem cells in patients with heart failure on left ventricular assist devices, presented by Dr. Eric A. Rose

  • Next-Generation Heart Muscle Cells: Advances in skeletal, myocardial, embryonic, and bone marrow derived techniques

  • A Preview of First-in-Human Studies Planned for the Coming Year
    • MARVEL: the largest randomized placebo-controlled study of skeletal myoblasts in patients with heart failure, presented by Dr. Warren Sherman
    • PRIMO-AMI; a novel bone-marrow derived cell and injection technique in patients with heart attack, presented by Dr. Marc Penn.

WHO: Hundreds of the worlds leading cell therapy experts will meet to discuss the latest advances in this area.

Warren Sherman, M.D., Conference Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patients own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN: January 16 18, 2008

WHERE: Columbia University, Alfred Lerner Hall, 2920 Broadway (at 115th St.), New York, NY

For media inquiries and registration, please contact Irma Damhuis (212-851-9187; idamhuis@crf.org) , Claire Laporte (212-851-9311; claporte@crf.org) or Alex Lyda (212-305-0820; mal2133@columbia.edu)

The conference program can be found at http://www.register-crf.org/data/product/Cell%20Therapy%20Brochure%20L08.pdf


'/>"/>

Contact: Claire Laporte
claporte@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related biology news :

1. Planetary geoscience, paleontology, and more at GSA Annual Meeting in Denver next month
2. CIC Again Named to Software Magazines Annual Prestigious Software 500 List
3. Colony collapse disorder symposium added to ESA Annual Meeting
4. Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings
5. Canadian Society of Exercise Physiology Annual Scientific Conference
6. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
7. ESMO International Symposium on Immunology
8. Conservation International and Toyota partner to protect Philippines rain forests
9. International team shows mercury concentrations in fish respond quickly to increased deposition
10. International team shows mercury concentrations in fish respond quickly to increased deposition
11. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... Dec. 8, 2016 Eutilex Co. Ltd. today ... (US $18.9M) Series A financing. This financing round included ... Venture and SNU Bio Angel. This new funding brings ... KRW (US $27.7M) since its founding in 2015. ... the development and commercialization of its immuno-oncology programs, expand ...
(Date:12/8/2016)... Dec. 8, 2016   Biocept, Inc . ... provider of clinically actionable liquid biopsy tests to ... clinical data featuring its Target Selectorâ„¢ Circulating Tumor ... for the detection of actionable biomarkers in patients ... sponsored by Sara Cannon Research Institute (SCRI), the ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new ... the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet ... population and timing of blood sampling may improve the value of a blood-based ...
Breaking Biology Technology: